When lifestyles sign

作     者：Maria Guarino Cedric Bovet Jean-Francois Dufour 

作者机构：HepatologyDepartment for BioMedical ResearchUniversity of BernBernSwitzerland GastroenterologyDepartment of Clinical Medicine and SurgeryUniversity of Naples“Federico II”NaplesItaly University Institute of Clinical ChemistryInselspitalUniversity of BernBernSwitzerland University Clinic of Visceral Surgery and MedicineInselspital BernBernSwitzerland 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2019年第8卷第1期

页      面：69-71页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：NAFLD diagnosis drugs 

摘      要：Nonalcoholic fatty liver disease(NAFLD)has a global prevalence of 25%,reflecting the global epidemic of obesity and diabetes(1).The onset and development of NAFLD are closely associated with dietary habits and lifestyle;consequently,lifestyle modifications including weight loss,increased physical activity,and dietary changes remain the treatment of choice for *** when drugs to treat non-alcoholic steatohepatitis will be available,lifestyle changes will remain an essential component of the therapeutic plan of these *** the last years,a strong association between lifestyle and hepatocellular carcinoma(HCC)has become evident(2-4).In patients with NAFLD,the annual incidence of HCC is 0.44 per 1,000 person/year and almost 50%of cases develops in a non-cirrhotic liver resulting in a diagnosis at an advanced stage with a worse prognosis(1,5).Nonetheless,the high prevalence of NAFLD with the relatively low risk for HCC makes a surveillance program cost-ineffective in non-cirrhotic patients(6).